DNA Microarray Market
Global Industry Analysis (2017 – 2020), Growth Trends and Market Forecast (2021 – 2025)
All interactions and sensitive information remain confidential.
Custom Research Service
Undertaking exclusive research tailored for your business.
The capability of DNA microarrays to conduct a comprehensive and concurrent analysis of thousands of genes has resulted in the success of this technology in the last decade. Technological progression in computational capabilities and robotics for microarray procedures have steered the rapid uptake of gene chips in clinical laboratories worldwide. Vendors are striving to develop innovative solutions for storage and analysis of microarray-generated information to facilitate biomedicine applications of the array technology.
Next-Generation Sequencing (NGS) Takes DNA Microarrays Head On
The DNA and gene chip industry is principally driven by a recent evolution in the areas of personalized medicine and cancer diagnostics. Many companies developing microarray technologies are catering to a vast majority of public institutes which include government laboratories, academic centers, and clinical research organizations. Though the popularity of Next Generation Sequencing (NGS) has skyrocketed recently, it is not completely replacing microarrays in diagnostics and cytogenetics due to its relatively high price and sturdy rate of clinical implementation.
Early Cancer Diagnosis Requirement is Driving Global DNA Microarray Market
Consumables captured the largest market share in the DNA microarray market in 2019 and this product segment is anticipated to hold a lion’s share during the forecast period. This growth is primarily on the account of technological advancements in gene expression analysis algorithms, together with ease of availability of reagents and other auxiliary components required for microarray procedures.
Cancer diagnosis and treatment was the dominant application in 2019 due to incremental demand for targeted cancer therapies. Drug discovery has set the ground to become fastest-growing application segment due to strong demand of genomic chip arrays for optimization for different drug discovery processes such as disease pathway identification, disease pathway validation, and compound screening.
Academic and government research institutes accounted for the largest market share in 2019. The segment is also expected to dominate the market till the end of the forecast period, 2025. Many government institutes are spending heavily on R&D activities. Multiple research projects are taking place in a wide range of applications.
Companies to Set Up Plants in Asia Pacific Region to Expand Regional Footprints
North America is the leading region as it is home for well-established players, innovative informatics infrastructure hub, and large-scale genomic R&D projects in the region. On the other hand, Asia Pacific is expected to register the highest CAGR over the forecast period as there is growing awareness regarding genetic tests for disease risk assessment and prevention.
Asia Pacific region will offer a massive growth prospect to the DNA microarray market as the region boasts a high population base and the substantial budget allocations by governments in developing countries towards the biotechnology sector.
Affymetrix, Inc (U.S.) and Illumina, Inc. (U.S.) have established their manufacturing facilities in the Asian sub-continent to take benefit from the growing demand and gain a competitive edge in the region.
Companies Explore Strategic Partnership Options to Gain Competitive Edge
PathogenDx, Inc., an Arizona-based technology company, which has developed a multiplexed microarray DNA-based pathogen testing platform, joined hands with Prevenio, an innovator and leader in providing automated food processing and pathogen protection systems to create the industry's first closed-loop system to address foodborne pathogens.